Media coverage
85
Media coverage
Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Morningstar.com Country/Territory United States Date 15/03/23 URL https://www.morningstar.com/news/accesswire/743817msn/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Street Insider Country/Territory United States Date 15/03/23 URL https://www.streetinsider.com/Accesswire/Protagonist+Therapeutics+Announces+Highly+Statistically+Significant+Results+from+the+Randomized+Withdrawal+Portion+of+the+REVIVE+Study+of+Rusfertide+in+Polycythemia+Vera/21373494.html Persons Ronald Hoffman Title Protagonist Therapeutics (PTGX) Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Street Insider Country/Territory United States Date 15/03/23 URL https://www.streetinsider.com/Corporate+News/Protagonist+Therapeutics+%28PTGX%29+Announces+Highly+Statistically+Significant+Results+from+the+Randomized+Withdrawal+Portion+of+the+REVIVE+Study+of+Rusfertide+in+Polycythemia+Vera/21373506.html Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet BioSpace Country/Territory United States Date 15/03/23 URL https://www.biospace.com/article/releases/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera/?s=71 Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Le Lezard.com Country/Territory Canada Date 15/03/23 URL https://www.lelezard.com/en/news-20812496.html Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Yahoo! Finance Country/Territory United States Date 15/03/23 URL https://finance.yahoo.com/news/protagonist-therapeutics-announces-highly-statistically-113000427.html Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet TD Ameritrade Country/Territory United States Date 15/03/23 URL https://research.tdameritrade.com/grid/public/markets/news/story.asp?fromPage=results&docKey=100-074w6973-1 Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Stockwatch Country/Territory Canada Date 15/03/23 URL www.stockwatch.com/News/Item/U-by0743817-U!PTGX-20230315/U/PTGX Persons Ronald Hoffman Title Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Market News Publishing Country/Territory United States Date 15/03/23 Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Accesswire Country/Territory United States Date 15/03/23 URL https://www.accesswire.com/743817/Protagonist-Therapeutics-Announces-Highly-Statistically-Significant-Results-from-the-Randomized-Withdrawal-Portion-of-the-REVIVE-Study-of-Rusfertide-in-Polycythemia-Vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant ... Media name/outlet PR inside Country/Territory Austria Date 15/03/23 URL https://www.pr-inside.com/protagonist-therapeutics-announces-highly-statistically-significant-r4910772.htm Persons Ronald Hoffman Title Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet FinanzNachrichten.de Country/Territory Germany Date 15/03/23 URL https://www.finanznachrichten.de/nachrichten-2023-03/58561375-protagonist-therapeutics-inc-protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-200.htm Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WCBD Country/Territory United States Date 15/03/23 URL https://www.counton2.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KSN Country/Territory United States Date 15/03/23 URL https://www.ksn.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet OurQuadCities.com Country/Territory United States Date 15/03/23 URL https://www.ourquadcities.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KNWA Country/Territory United States Date 15/03/23 URL https://www.nwahomepage.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KGET Country/Territory United States Date 15/03/23 URL https://www.kget.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WeAreGreenBay.com Country/Territory United States Date 15/03/23 URL https://www.wearegreenbay.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WFXRTV.com Country/Territory United States Date 15/03/23 URL https://www.wfxrtv.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KXNet.com Country/Territory United States Date 15/03/23 URL https://www.kxnet.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WBOY Country/Territory United States Date 15/03/23 URL https://www.wboy.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WYTV News Country/Territory United States Date 15/03/23 URL https://www.wytv.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WBTW News13 Country/Territory United States Date 15/03/23 URL https://www.wbtw.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet ABC 4 Country/Territory United States Date 15/03/23 URL https://www.abc4.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WSPA.com Country/Territory United States Date 15/03/23 URL https://www.wspa.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WIProud.com Country/Territory United States Date 15/03/23 URL https://www.wiproud.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WYOU Country/Territory United States Date 15/03/23 URL https://www.pahomepage.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WETM 18 Country/Territory United States Date 15/03/23 URL https://www.mytwintiers.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WOWK Country/Territory United States Date 15/03/23 URL https://www.wowktv.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KTSM.com Country/Territory United States Date 15/03/23 URL https://www.ktsm.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Wavy Country/Territory United States Date 15/03/23 URL https://www.wavy.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet My Champlain Valley Country/Territory United States Date 15/03/23 URL https://www.mychamplainvalley.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Binghamton Homepage Country/Territory United States Date 15/03/23 URL https://www.binghamtonhomepage.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet LocalSRY.com Country/Territory United States Date 15/03/23 URL https://www.localsyr.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet FOX 59 Country/Territory United States Date 15/03/23 URL https://fox59.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KSNT TV Country/Territory United States Date 15/03/23 URL https://www.ksnt.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WSAV Country/Territory Georgia Date 15/03/23 URL https://www.wsav.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WDTN Country/Territory United States Date 15/03/23 URL https://www.wdtn.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Fox 4 WDAF TV Country/Territory United States Date 15/03/23 URL https://fox4kc.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Valleycentral.com Country/Territory United States Date 15/03/23 URL https://www.valleycentral.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WCIA.com Country/Territory United States Date 15/03/23 URL https://www.wcia.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KODE TV Country/Territory United States Date 15/03/23 URL https://www.fourstateshomepage.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WTVW FOX 7 Country/Territory United States Date 15/03/23 URL https://www.tristatehomepage.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Myarklamiss.com Country/Territory United States Date 15/03/23 URL https://www.myarklamiss.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WWLP.com Country/Territory United States Date 15/03/23 URL https://www.wwlp.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet 8 News Now Country/Territory United States Date 15/03/23 URL https://www.8newsnow.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WJTV.com Country/Territory United States Date 15/03/23 URL https://www.wjtv.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Fox40 KTXL Country/Territory United States Date 15/03/23 URL https://fox40.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KELOLAND TV Country/Territory United States Date 15/03/23 URL https://www.keloland.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet FOX21News.com Country/Territory United States Date 15/03/23 URL https://www.fox21news.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet YourCentralValley.com Country/Territory United States Date 15/03/23 URL https://www.yourcentralvalley.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WJET Country/Territory United States Date 15/03/23 URL https://www.yourerie.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WJBF-TV Country/Territory Georgia Date 15/03/23 URL https://www.wjbf.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Kark.com Country/Territory United States Date 15/03/23 URL https://www.kark.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet ABC 27 Country/Territory United States Date 15/03/23 URL https://www.abc27.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WYZZ-TV Country/Territory United States Date 15/03/23 URL https://www.centralillinoisproud.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet CW33 NewsFix Country/Territory United States Date 15/03/23 URL https://cw33.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet CNYHomepage.com Country/Territory United States Date 15/03/23 URL https://www.cnyhomepage.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WIAT TV Country/Territory United States Date 15/03/23 URL https://www.cbs42.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WATE Country/Territory United States Date 15/03/23 URL https://www.wate.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WVNS Country/Territory United States Date 15/03/23 URL https://www.wvnstv.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet MyStateLine.com Country/Territory United States Date 15/03/23 URL https://www.mystateline.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WKRG Country/Territory United States Date 15/03/23 URL https://www.wkrg.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet OzarksFirst.com Country/Territory United States Date 15/03/23 URL https://www.ozarksfirst.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WTRF Country/Territory United States Date 15/03/23 URL https://www.wtrf.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet INFORMNNY.com Country/Territory United States Date 15/03/23 URL https://www.informnny.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WLNS Country/Territory United States Date 15/03/23 URL https://www.wlns.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet MyHighPlains.com Country/Territory United States Date 15/03/23 URL https://www.myhighplains.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WRBL-TV Country/Territory Georgia Date 15/03/23 URL https://www.wrbl.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KRQE Country/Territory United States Date 15/03/23 URL https://www.krqe.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet CBS4Indy Country/Territory United States Date 15/03/23 URL https://cbs4indy.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet ConchoValleyHomepage.com Country/Territory United States Date 15/03/23 URL https://www.conchovalleyhomepage.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WNCT Country/Territory United States Date 15/03/23 URL https://www.wnct.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Big Country Country/Territory United States Date 15/03/23 URL https://www.bigcountryhomepage.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WPRI Country/Territory United States Date 15/03/23 URL https://www.wpri.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WTAJ-TV Country/Territory United States Date 15/03/23 URL https://www.wtaj.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WHNT-TV Country/Territory United States Date 15/03/23 URL https://whnt.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Texomashomepage.com Country/Territory United States Date 15/03/23 URL https://www.texomashomepage.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KLFY Country/Territory United States Date 15/03/23 URL https://www.klfy.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WKRN Country/Territory United States Date 15/03/23 URL https://www.wkrn.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet Rochesterfirst.com Country/Territory United States Date 15/03/23 URL https://www.rochesterfirst.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WRIC TV Country/Territory United States Date 15/03/23 URL https://www.wric.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WesternSlopeNow.com Country/Territory United States Date 15/03/23 URL https://www.westernslopenow.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet KHON 2 Country/Territory United States Date 15/03/23 URL https://www.khon2.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman Title Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera Media name/outlet WNTZ Country/Territory United States Date 15/03/23 URL https://www.cenlanow.com/business/press-releases/accesswire/743817/protagonist-therapeutics-announces-highly-statistically-significant-results-from-the-randomized-withdrawal-portion-of-the-revive-study-of-rusfertide-in-polycythemia-vera Persons Ronald Hoffman